Biotech Stocks Facing FDA Decision In April

In March, the FDA approved two novel drugs. Trogarzo, a new HIV treatment for patients who have limited treatment options, was approved on March 6, 2018, and Ilumya, for the treatment of adults with moderate-to-severe plaque psoriasis, was approved on March 21, 2018. Now, let's take a look at the biotech stocks that await a ruling from the FDA in April 2018.

from RTT - Biotech https://ift.tt/2Gz8YBz
via IFTTT